Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025
Daidzein alleviates ethanol-induced acute gastric injury in rats by targeting ESR1 and activating the PI3K/AKT/CREB signaling pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Tao, Du Shengyi, Wang Zexin, Hu Qichao, Zeng Lingshun, Chen Yuan, Tan Xiyue, Zeng Yi, Fu Lingping, Hu Fangli, Xiao Kun, Ma Xiao, Zeng Jinhao, Zhao Yanling
Аннотация
BACKGROUND: Alcohol-induced gastric ulcers (GU) rank among the most prevalent upper gastrointestinal diseases, severely impacting patients' quality of life and health. Daidzein (DAI), one of the primary active compounds present in soybeans and other edible plants, has been reported to exert potential therapeutic effects on GU.
PURPOSE: This study sought to explore the potential mechanisms through which DAI alleviates alcohol-induced acute GU in rats.
METHODS: In this study, in vitro and in vivo models of alcohol-induced GU were established and employed a range of experimental techniques, including Immunofluorescence (IF), Cellular thermal shift assay (CETSA), Transmission Electron Microscopy (TEM), Immunohistochemistry (IHC), Western Blotting (WB), and Real-time quantitative PCR (RT- qPCR), to assess the protective effects of DAI. Next, network pharmacology, virtual screening, and molecular dynamics simulations were employed to identify the potential targets and mechanisms responsible for DAI's therapeutic action on GU. Finally, the activation of the PI3K/AKT/CREB signaling pathway was validated in both a rat model and a GES-1 cell model.
RESULTS: DAI was shown to alleviate inflammation, oxidative stress, and apoptosis, while mitigating the reduction of H⁺/K⁺-ATPase and EGFR, thereby restoring the gastric barrier. In both in vitro and in vivo models, DAI showed stable binding to key residues of ESR1 (Leu387A, Arg394A, His524A, and Glu353A), and subsequently activated the PI3K/AKT/CREB signaling pathway. Notably, Fulvestrant (a selective ESR1 inhibitor) and LY294002 (a PI3K inhibitor) both abrogated the activation of this pathway.
CONCLUSION: DAI inhibited apoptosis and preserved mucosal integrity by targeting ESR1 to activate the PI3K/AKT/CREB signaling pathway. The research elucidated the mechanisms and clinical value of DAI in the treatment of GU, offering a reference for its application as a gastric mucosal protectant in drug development and dietary supplements.
PURPOSE: This study sought to explore the potential mechanisms through which DAI alleviates alcohol-induced acute GU in rats.
METHODS: In this study, in vitro and in vivo models of alcohol-induced GU were established and employed a range of experimental techniques, including Immunofluorescence (IF), Cellular thermal shift assay (CETSA), Transmission Electron Microscopy (TEM), Immunohistochemistry (IHC), Western Blotting (WB), and Real-time quantitative PCR (RT- qPCR), to assess the protective effects of DAI. Next, network pharmacology, virtual screening, and molecular dynamics simulations were employed to identify the potential targets and mechanisms responsible for DAI's therapeutic action on GU. Finally, the activation of the PI3K/AKT/CREB signaling pathway was validated in both a rat model and a GES-1 cell model.
RESULTS: DAI was shown to alleviate inflammation, oxidative stress, and apoptosis, while mitigating the reduction of H⁺/K⁺-ATPase and EGFR, thereby restoring the gastric barrier. In both in vitro and in vivo models, DAI showed stable binding to key residues of ESR1 (Leu387A, Arg394A, His524A, and Glu353A), and subsequently activated the PI3K/AKT/CREB signaling pathway. Notably, Fulvestrant (a selective ESR1 inhibitor) and LY294002 (a PI3K inhibitor) both abrogated the activation of this pathway.
CONCLUSION: DAI inhibited apoptosis and preserved mucosal integrity by targeting ESR1 to activate the PI3K/AKT/CREB signaling pathway. The research elucidated the mechanisms and clinical value of DAI in the treatment of GU, offering a reference for its application as a gastric mucosal protectant in drug development and dietary supplements.